A retrospective, observational study to evaluate glycemic control over a 2 year follow-up period in type-2 diabetes patients on dulaglutide

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

23 May 2022 Results evaluating the clinical characteristics and treatment outcomes for early or late initiation of dulaglutide therapy in patients with type 2 diabetes, published in the Clinical Therapeutics.
29 Jun 2021 Results assesseing glycemic control over a 6-month follow-up in in Patients with Type 2 Diabetes who initiated dulaglutide following oral antihyperglycemic drugs, presented at the 81st Annual Scientific Sessions of the American Diabetes Association
01 Nov 2020 Primary endpoint, Change in A1C, has been met as per Results published in the Clinical Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com